TY  - JOUR
AU  - van Vliet, Erwin
AU  - Daneshian, Mardas
AU  - Beilmann, Mario
AU  - Davies, Anthony
AU  - Fava, Eugenio
AU  - Fleck, Roland
AU  - Julé, Yvon
AU  - Kansy, Manfred
AU  - Kustermann, Stefan
AU  - Macko, Peter
AU  - Mundy, William R
AU  - Roth, Adrian
AU  - Shah, Imran
AU  - Uteng, Marianne
AU  - van de Water, Bob
AU  - Hartung, Thomas
AU  - Leist, Marcel
TI  - Current approaches and future role of high content imaging in safety sciences and drug discovery.
JO  - Alternatives to animal experimentation
VL  - 31
IS  - 4
SN  - 1868-596X
CY  - Heidelberg
PB  - Springer
M1  - DZNE-2020-03969
SP  - 479-493
PY  - 2014
AB  - High content imaging combines automated microscopy with image analysis approaches to simultaneously quantify multiple phenotypic and/or functional parameters in biological systems. The technology has become an important tool in the fields of safety sciences and drug discovery, because it can be used for mode-of-action identification, determination of hazard potency and the discovery of toxicity targets and biomarkers. In contrast to conventional biochemical endpoints, high content imaging provides insight into the spatial distribution and dynamics of responses in biological systems. This allows the identification of signaling pathways underlying cell defense, adaptation, toxicity and death. Therefore, high content imaging is considered a promising technology to address the challenges for the 'Toxicity testing in the 21st century' approach. Currently, high content imaging technologies are frequently applied in academia for mechanistic toxicity studies and in pharmaceutical industry for the ranking and selection of lead drug compounds or to identify/confirm mechanisms underlying effects observed in vivo. A recent workshop gathered scientists working on high content imaging in academia, pharmaceutical industry and regulatory bodies with the objective to compile the state-of-the-art of the technology in the different institutions. Together they defined technical and methodological gaps, proposed quality control measures and performance standards, highlighted cell sources and new readouts and discussed future requirements for regulatory implementation. This review summarizes the discussion, proposed solutions and recommendations of the specialists contributing to the workshop.
KW  - Animal Testing Alternatives
KW  - Animals
KW  - Drug Discovery: methods
KW  - Hazardous Substances
KW  - Imaging, Three-Dimensional: methods
KW  - Models, Biological
KW  - Pharmaceutical Preparations
KW  - Predictive Value of Tests
KW  - Reproducibility of Results
KW  - Toxicity Tests: methods
KW  - Hazardous Substances (NLM Chemicals)
KW  - Pharmaceutical Preparations (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25027442
DO  - DOI:10.14573/altex.1405271
UR  - https://pub.dzne.de/record/137647
ER  -